Skip to Main Content

Paper Details

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Blood
45
2022
ET, ET/, Hydroxyurea, IFN-?, JAK2V617F, Myeloproliferative Disorders, PEG, PV, Thrombotic, essential thrombocythemia, hydroxyurea, interferon, interferon-, patients, pegylated IFN-?, polycythemia vera
Author NameAffiliation
Judith D Goldberg
Judith D GoldbergNew York University School of Medicine
Judith D Goldberg
Judith D GoldbergNew York University School of Medicine
  • 1 - 4

Datasets

Release 1.2